Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Olaris
Framingham, Massachusetts, United States
- Ownership
- Private
- Employees
- ~11
- Development stage
- Other
01
Overview
Olaris has demonstrated the ability of its platform technology to predict patient response to therapies in oncology (e.g., trastuzumab for HER2-positive breast cancer), neurodegeneration (Parkinson’s), and transplant rejection, using metabolomic biomarkers. Publications and presentations suggest promising results in distinguishing responders vs. non-responders and in uncovering new metabolic signatures relevant to disease and treatment outcomes[2][3].
- Therapeutic areas
- OncologyNeurologyImmunology
- Modalities
- Diagnostic platform
- Industry
- Metabolite Diagnostics
02
Partnerships
Beyond the preview
Go deeper on Olaris.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Olaris.